+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Hereditary Angioedema Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997607
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • CSL Behring
  • Ionis Pharmaceuticals
  • Pharming Healthcare, Inc.
  • Shire US Inc.
  • MORE
The Hereditary Angioedema Therapeutics market is projected to grow with a CAGR of nearly 9.3% over the forecast period. The major factor attributing to the growth of the market is the increasing awareness of the treatment for the rare diseases such as hereditary angiodema. The condition is believed to affect about 1 in 50,000 people. Attacks take the form of sudden, regularly painful swelling in numerous parts of the body, involving the abdomen, extremities, throat, and face. Many organisations are spreading awareness about the diseases and its treatment, like the US Hereditary Angioedema Association, is a non-profit organisation dedicated to offering the HAE patients access to the latest treatment options and dependable, personal support to address symptoms and the challenges associated with the condition. Furthermore, increasing funding for rare genetic diseases and orphan drugs by the governments is also enhancing the market growth. However, misdiagnosis of the condition, as common allergies, appendicitis, and Irritable Bowel Syndrome, has steered to a interruption in efficient treatment, which has had a considerable negative impact on the growth of the global hereditary angioedema treatment market.

Key Market Trends

Subcutaneous Injection Segment is the Fastest Growing in the Hereditary Angioedema Therapeutics Market

The remarkable growth of subcutaneous injections as a mode of drug administration can be credited to the demand for ease-of-usage for patients, which has had an instrumental impact on the growth of this segment. Apart from the advantages of subcutaneous mode of administration , the other factors boosting the growth of the segment are the increasing awareness of the treatment and increasing research and development and funding for orphan drug development and for rare genetic disorders. Ministry of Health and Family Welfare India, formulated a National Policy for treatment of Rare Diseases in India to progressively build India’s capacity to respond comprehensively to rare diseases released a funding of initial amount of Rs. 100 crore towards funding treatment of rare genetic diseases. Hence, the increasing funding for research and development for new drugs is propelling the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, awareness programs and organisations regarding the treatment of the condition, established healthcare infrastructure. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market.

Competitive Landscape

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies which are currently dominating the market are CSL Behring, Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Adverum Biotechnologies, Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • CSL Behring
  • Ionis Pharmaceuticals
  • Pharming Healthcare, Inc.
  • Shire US Inc.
  • MORE
1.1 Study Deliverable
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness Levels for Hereditary Angioedema
4.2.2 Increasing Research and Development and Funding for Orphan Drug Development
4.3 Market Restraints
4.3.1 Misdiagnosis of Hereditary Angioedema
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 C1 Esterase Inhibitor
5.1.2 Selective Bradykinin B2 Receptor Antagonist
5.1.3 Kallikrein Inhibitor
5.1.4 Others
5.2 By Route of Administration
5.2.1 Intravenous
5.2.2 Subcutaneous Injection
5.2.3 Oral
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 CSL Behring
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Shire US Inc.
6.1.4 Pharming Healthcare, Inc.
6.1.5 BioCryst Pharmaceuticals, Inc.
6.1.6 Attune Pharmaceuticals, Inc.
6.1.7 Ionis Pharmaceuticals
6.1.8 KalVista Pharmaceuticals, Inc
6.1.9 Adverum Biotechnologies, Inc

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • CSL Behring
  • Takeda Pharmaceutical Company Limited
  • Shire US Inc.
  • Pharming Healthcare, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Attune Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals, Inc
  • Adverum Biotechnologies, Inc
Note: Product cover images may vary from those shown